D

D.Western Therapeutics Institute Inc
TSE:4576

Watchlist Manager
D.Western Therapeutics Institute Inc
TSE:4576
Watchlist
Price: 102 JPY 0.99% Market Closed
Market Cap: ¥5.5B

Operating Margin

-248.5%
Current
Declining
by 57.5%
vs 3-y average of -191%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-248.5%
=
Operating Income
¥-1B
/
Revenue
¥419.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-248.5%
=
Operating Income
¥-1B
/
Revenue
¥419.8m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
D.Western Therapeutics Institute Inc
TSE:4576
5.4B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-248.5%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

D.Western Therapeutics Institute Inc
Glance View

Market Cap
5.5B JPY
Industry
Biotechnology

D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken and currently employs 19 full-time employees. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.

D.Western Therapeutics Institute Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-248.5%
=
Operating Income
¥-1B
/
Revenue
¥419.8m
What is D.Western Therapeutics Institute Inc's current Operating Margin?

The current Operating Margin for D.Western Therapeutics Institute Inc is -248.5%, which is below its 3-year median of -191%.

How has Operating Margin changed over time?

Over the last 3 years, D.Western Therapeutics Institute Inc’s Operating Margin has decreased from -75.7% to -248.5%. During this period, it reached a low of -256.5% on Dec 31, 2024 and a high of -68.3% on Dec 31, 2022.

Back to Top